REG - Morgan Stanley Cap - Rule 38.5 - ABBVIE INC.

Morgan StanleyAnnouncement

12/03/2020 11:00

RNS Number : 9105F
  
Morgan Stanley Capital Services LLC
  
12 March 2020
  
 

 
 FORM 38.5 
 
IRISH TAKEOVER PANEL
 
DISCLOSURE UNDER RULE 38.5 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER  RULES, 2007 (AS AMENDED)
 
DEALINGS BY CONNECTED EXEMPT MARKET-MAKERS
 
1.             KEY INFORMATION



 Name of exempt market-maker


   Morgan Stanley Capital Services LLC




 Company dealt in


   ABBVIE INC.




 Class of relevant security to which the dealings being disclosed relate (Note 1)


  US$0.01 COMMON STOCK




 Date of dealing


   11 MARCH 2020



 
 
2.             DEALINGS (Note 2)
 
(a)           Purchases and sales



 Total number of relevant secuities accquired


 Highest price paid (Note 3)


 Lowest price paid (Note 3)




  102,085


 85.7600 USD


 83.6200 USD



 



 Total number of relevant secuities disposed


 Highest price paid (Note 3)


 Lowest price paid (Note 3)




  63,615


 86.4200 USD


 83.6000 USD



 
 
(b)           Derivatives transactions (other than options transactions)
 



 Product name, e.g. CFD


 Nature of transaction 
                (Note 4)


 Number of relevant securities 
                (Note 5)


 Price per unit




 CFD


 LONG


 4,330


 84.4231 USD




 CFD


 LONG


 18


 84.4700 USD




 CFD


 LONG


 100


 84.8450 USD




 CFD


 LONG


 100


 84.8450 USD




 CFD


 LONG


 11


 84.8500 USD




 CFD


 LONG


 190


 84.8500 USD




 CFD


 LONG


 6,300


 84.8500 USD




 CFD


 LONG


 9,374


 84.8554 USD




 CFD


 LONG


 1,100


 84.9314 USD




 CFD


 LONG


 2,000


 84.9514 USD




 CFD


 LONG


 4,232


 85.5522 USD




 CFD


 LONG


 5,525


 85.5837 USD




 CFD


 LONG


 2,067


 85.7599 USD




 CFD


 LONG


 953


 85.7600 USD




 CFD


 LONG


 67


 85.7600 USD




 CFD


 LONG


 2,432


 85.7600 USD




 CFD


 LONG


 4,322


 85.7600 USD




 CFD


 SHORT


 5


 84.0000 USD




 CFD


 SHORT


 47,814


 84.3049 USD




 CFD


 SHORT


 6,300


 84.4595 USD




 CFD


 SHORT


 2,000


 84.8390 USD




 CFD


 SHORT


 11


 84.8500 USD




 CFD


 SHORT


 100


 84.8500 USD




 CFD


 SHORT


 587


 84.8500 USD




 CFD


 SHORT


 320


 85.1230 USD




 CFD


 SHORT


 49


 85.1230 USD




 CFD


 SHORT


 64


 85.3800 USD




 CFD


 SHORT


 100


 85.4300 USD




 CFD


 SHORT


 12,572


 85.5017 USD




 CFD


 SHORT


 418


 85.5017 USD




 CFD


 SHORT


 5,275


 85.7600 USD



 
 
(c)            Options transactions in respect of existing relevant securities
 
i)           Writing, selling, purchasing or varying
 



 Product name, eg call option


 Writing, selling, purchasing, varying etc


 Number of securities to which the option relates (Note 5)


 Exercise Price


 Type, e.g American, European etc 


 Expiry Date 


 Option money paid/received per unit (Note 3)




 N/A


 N/A


 N/A


 N/A


 N/A


 N/A


 N/A 



 
(ii) Exercising
 



 Product name, eg call option


 Number of securities


 Exercise price per unit (Note 3)




 N/A


 N/A


 N/A  



 
 
3. OTHER INFORMATION
 
Agreements, arrangements or understandings relating to options or derivatives
 



Full Details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
 




 
 
 
 
 



 
 



 Date of disclosure


 12 MARCH 2020




 Contact Name


Craig Horsley




 Telephone Number


+44(141) 245 7736 




 Name of offeree/offeror with which connected


ABBVIE INC. 




Nature of connection (Note 6)


Advisory 



 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
ISEUUVKRRNUOARR